In order to enhance competitiveness, pharmaceutical companies are vigorously building R&D production bases

【Pharmaceutical Network Industry News】Recently, the "New Leading (Chongqing) Biomedical Integration R&D Service Base" project invested and built by Beijing New Leading Pharmaceutical Science and Technology Development Co.
, Ltd.
was also completed and put into use in Yongchuan District, which is the first biomedical integrated R&D service base project
built and put into use in Yongchuan.
It is reported that the total investment of the project is 2.
4 billion yuan, and the first phase of the new leading (Chongqing) research branch and the new leading (Chongqing) MAH company have been built, and the second phase will build a cell gene therapy CRO company, CDMO base, Chongqing MAH information platform and management center
.
After the completion of the base, it can provide pharmaceutical companies with "one-stop" R&D and production services for the whole industry chain such as drug project approval, drug registration, clinical CRO, CDMO and MAH
.
It is understood that the construction of the project is the research and development and production of small molecule CDMO chemical raw materials and APIs, and the construction of small molecule CDMO drug preparations, drug research and development, and new technology promotion and application will be expanded in the
future.
The project is planned to be designed as a whole, built in phases, and put into operation
in batches.
It is worth noting that before this, Kai Laiying also announced that it signed an investment agreement with the Administrative Committee of Taixing Economic Development Zone in Jiangsu Province on the "Investment Agreement on the Construction of "Biomedical R&D and Production Integrated Base Project", and the company intends to invest 4-5 billion yuan in Taixing to invest in the biomedical R&D and production integration base project
.
In addition, on September 20, Medi Northwest Shanghai Biomedical R&D and Innovation Industry Base Project issued four certificates at the same time, realizing "starting construction after taking the land"
.
The total investment of the project is 1.
57 billion yuan, covering an area of 66.
9 acres, with a construction area of 141,500 square meters
.
After completion, Medicipuri will combine the advanced technology and cutting-edge research field of global drug research and development, establish a perfect one-stop drug research and development platform with the ability to guide domestic new drug research and innovation, and creatively combine a variety of technology platforms to explore and form a higher level of drug research and development scientific support and laboratory research and development pillars
.
In fact, in addition to the above pharmaceutical companies, many Chinese pharmaceutical companies have announced the establishment of new R&D production bases
this year.
For example, on August 30, Hualan Bio said on the investor interactive platform that Hualan Biomedical R&D and intelligent production base has begun construction
.
The base will meet the production capacity needs of human blood albumin, intravenous human immunoglobulin and other products, and the company is expected to further improve the industrial layout and enhance its core competitiveness
after expanding the production scale 。 In July, WuXi AppTec publicly announced that it expects to invest S$2 billion (approximately RMB9.
73 billion) in R&D and production facilities in Singapore over the next ten years.
In the same month, WuXi AppTec subsidiary Hequan Pharmaceutical announced that its new oligonucleotide and peptide production building in Changzhou's API R&D and production base was officially put into operation.
In February, Kingsray Biotech announced that the company's Asia-Pacific Singapore production and R&D base was officially put into operation.
.
.
Industry analysts believe that a large number of enterprises have begun to build R&D production bases, on the one hand, in order to accelerate industrial upgrading and enhance production, distribution and other capabilities; On the other hand, in order to further expand the company's production capacity and improve market competitiveness
.
The industry expects that in the future, in the context of the vigorous development of the pharmaceutical industry, especially innovative drugs, the construction of R&D production bases by pharmaceutical companies will become the norm
in order to enhance their competitiveness.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.